Skip to main content
NewslettersWatchlist

Biovaxys Technology Corp(BVAXF)
OTC US

Today's Change
Delayed Last Update
Day Low0.0620
Day High0.0620
Open:0.0620
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newswire.ca
BioVaxys Technology Corp. Announces Failure to File Cease Trade Order
Newswire.ca
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
Newswire.ca
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
BayStreet.ca
Promising Outlook as Biotech Sector Advances Cancer Treatments Amidst Rising Diagnoses
Newswire.ca
BIOVAXYS APPOINTS CHRISTOPHER CHERRY AS CHIEF FINANCIAL OFFICER
BayStreet.ca
Navigating the Surge in Aquaculture: Opportunities & Challenges
Newswire.ca
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
Newswire.ca
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
Newswire.ca
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
Newswire.ca
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE
Newswire.ca
BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT
Newswire.ca
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
Newswire.ca
BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order
Newswire.ca
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
Newswire.ca
BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications
Newswire.ca
Annual Financial Statements Update for the Year Ended October 31, 2023
Newswire.ca
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
Newswire.ca
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
Newswire.ca
BIOVAXYS ANNOUNCES COMPLETION OF FINAL TRANCHE OF PRIVATE PLACEMENT
Newswire.ca
BIOVAXYS ANNOUNCES COMPLETION OF FIRST TRANCHE OF PRIVATE PLACEMENT
Newswire.ca
BIOVAXYS ANNOUNCES COMPLETION OF FIRST TRANCHE OF PRIVATE PLACEMENT
Newswire.ca
BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT
Newswire.ca
BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT AND DEBT SETTLEMENT
Newswire.ca
BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition
Newswire.ca
BioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare
Newswire.ca
BioVaxys in Non-Binding Discussions for Major Immunotherapeutics Technology Acquisition
Newswire.ca
BioVaxys and The Ohio State University Extend Research Collaboration
PR Newswire
BIOVAXYS ANNOUNCES MANAGEMENT CHANGE
Newsfile
BioVaxys Announces Sale of TAET Software Co
Newswire.ca
BIOVAXYS ANNOUNCES SALE OF TAET SOFTWARE CO
PR Newswire
BIOVAXYS REPORTS AGM RESULTS
PR Newswire
BIOVAXYS RETAINS MAXIM GROUP AS FINANCIAL ADVISOR AND INVESTMENT BANKER

Profile

N/A

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.